Type de paiement: | T/T,L/C,D/A,Western Union |
Incoterm: | FOB |
Quantité de commande minimum: | 1 Gram |
Description du produit
.cp_wz table {border-top : 1px solide #ccc;border-left:1px solide #ccc ; } .cp_wz table td{border-right : 1px solide #ccc ; border-bottom : 1px solide #ccc ; remplissage : 5px 0px 0px 5px;} .cp_wz table th {border-right : 1px solid #ccc;border-bottom : 1px solid #ccc ; rembourrage : 5px 0px 0px 5px ;}
Poids moléculaire :
627.73 Le dabigatran Etexilate est le promédicament du dabigatran, une puissante petite molécule non peptidique qui inhibe spécifiquement et de manière réversible la thrombine libre et liée au caillot en se liant au site actif du molécule de thrombine.
Activité biologique
Description
|
Dabigatran Etexilate is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.
|
In vitro
|
Dabigatran selectively and reversibly inhibits human thrombin (Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC50: 10 nM), while showing no inhibitory effect on other platelet-stimulating agents. Dabigatran selectively and reversibly inhibits human thrombin (Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC50: 10 nM), while showing no inhibitory effect on other platelet-stimulating agents. Dabigatran inhibits thrombin generation in platelet-poor plasma (PPP) with IC50 of 0.56 μM, measured as the endogenous thrombin potential (ETP). Dabigatran demonstrates concentrationdependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 μM, respectively. [1]
|
In vivo
|
Dabigatran prolongs the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). [1] Dabigatran etexilate (20 mg/kg, orally) produces less prolongation of K value and less decreases in angle and maximum amplitude than enoxaparin in swine. [2] Dabigatran (0.01-0.1 mg/kg) reduces thrombus formation dose-dependently, with an ED50 (50% of the effective dose) of 0.033 mg/kg and complete inhibition at 0.1 mg/kg. Dabigatran etexilate (5-30 mg/kg) inhibits thrombus formation in a dose- and time-dependent manner, with maximum inhibition within 30 min of pretreatment, suggesting a rapid onset of action.[3]
|
Features
|
|
Protocole (uniquement à titre de référence) Conversion de différents animaux modèles sur la base de la BSA (valeur basée sur les données des lignes directrices provisoires de la FDA)
Species
|
Baboon
|
Dog
|
Monkey
|
Rabbit
|
Guinea pig
|
Rat
|
Hamster
|
Mouse
|
Weight (kg)
|
12
|
10
|
3
|
1.8
|
0.4
|
0.15
|
0.08
|
0.02
|
Body Surface Area (m2)
|
0.6
|
0.5
|
0.24
|
0.15
|
0.05
|
0.025
|
0.02
|
0.007
|
Km factor
|
20
|
20
|
12
|
12
|
8
|
6
|
5
|
3
|
Animal A (mg/kg) = Animal B (mg/kg) multiplied by
|
Animal B Km
|
Animal A Km
|
Par exemple, pour modifier la dose de resvératrol utilisée pour une souris (22,4 mg/kg) à une dose basée sur la BSA pour un rat, multiplier 22,4 mg/kg par le facteur Km pour une souris puis diviser par le facteur Km pour un rat. Ce calcul donne une dose équivalente chez le rat pour le resvératrol de 11,2 mg/kg.
Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×
|
mouse Km(3)
|
= 11.2 mg/kg
|
rat Km(6)
|
1 Références [1] Wienen W, et al. Thromb Haemost, 2007, 98(1), 155-162. [2] McKellar SH, et al. J Thorac Cardiovasc Surg, 2011, 141 (6), 1410-1416. [3] Wienen W, et al. Thromb Haemost, 2007, 98(2), 333-338.
Informations chimiques
Molecular Weight (MW)
|
627.73
|
Formula
|
C34H41N7O5
|
CAS No.
|
211915-06-9
|
Storage
|
3 years -20℃Powder
|
6 months-80℃in solvent (DMSO, water, etc.)
|
Synonyms
|
BIBR-1048
|
Solubility (25°C) *
|
In vitro
|
DMSO
|
126 mg/mL
(200.72 mM)
|
Water
|
<1 mg/mL
(
|
Ethanol
|
12 mg/mL
(19.11 mM)
|
|
Chemical Name
|
(E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
|
Stock Solution (1ml DMSO)
|
1mM
|
10mM
|
20mM
|
30mM
|
Mass(mg)
|
0.62773
|
6.2773
|
12.5546
|
18.8319
|
Groupes de Produits : Autres > Inhibiteur de thrombine